Overview

Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)

Status:
Not yet recruiting
Trial end date:
2024-02-23
Target enrollment:
Participant gender:
Summary
The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with mild to moderately active Systemic Lupus Erythematosus (SLE). Participants will be treated for 4 or 12 weeks followed by an 8-week follow-up period.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals